PL2323623T3 - Kompozycje farmaceutyczne - Google Patents

Kompozycje farmaceutyczne

Info

Publication number
PL2323623T3
PL2323623T3 PL09806425T PL09806425T PL2323623T3 PL 2323623 T3 PL2323623 T3 PL 2323623T3 PL 09806425 T PL09806425 T PL 09806425T PL 09806425 T PL09806425 T PL 09806425T PL 2323623 T3 PL2323623 T3 PL 2323623T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL09806425T
Other languages
English (en)
Inventor
Karin Schönhammer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08165662A external-priority patent/EP2172189A1/en
Priority claimed from EP09151917A external-priority patent/EP2213307A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2323623T3 publication Critical patent/PL2323623T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09806425T 2008-08-12 2009-08-11 Kompozycje farmaceutyczne PL2323623T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08162213 2008-08-12
EP08165662A EP2172189A1 (en) 2008-10-01 2008-10-01 Pharmaceutical Compositions
EP09151917A EP2213307A1 (en) 2009-02-03 2009-02-03 Injectable depot formulations
EP09806425.6A EP2323623B1 (en) 2008-08-12 2009-08-11 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PL2323623T3 true PL2323623T3 (pl) 2017-04-28

Family

ID=41020843

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09806425T PL2323623T3 (pl) 2008-08-12 2009-08-11 Kompozycje farmaceutyczne

Country Status (14)

Country Link
US (1) US9155696B2 (pl)
EP (1) EP2323623B1 (pl)
JP (2) JP5951991B2 (pl)
KR (1) KR101626632B1 (pl)
CN (1) CN102119022B (pl)
AU (1) AU2009281223B2 (pl)
BR (1) BRPI0917975A2 (pl)
CA (1) CA2731316C (pl)
ES (1) ES2600797T3 (pl)
MX (1) MX347056B (pl)
PL (1) PL2323623T3 (pl)
PT (1) PT2323623T (pl)
RU (1) RU2504360C2 (pl)
WO (1) WO2010018159A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
BR112012017435A2 (pt) 2010-01-13 2020-08-25 Ipsen Pharma S.A.S processo para a preparação de composições farmacêuticas para a liberação sustentada de análogos de somatostatina
AU2011227532B2 (en) * 2010-03-15 2014-03-13 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
ES2589106T3 (es) * 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
RU2015115649A (ru) * 2012-09-27 2016-11-20 Октафарма Аг Тест на гемолитический потенциал фармацевтических продуктов и составов для минимизации риска
WO2014159863A1 (en) * 2013-03-14 2014-10-02 Genzyme Corporation Thermo-sensitive bone growth compositions
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
WO2015133580A1 (ja) * 2014-03-05 2015-09-11 わかもと製薬株式会社 注入可能なポリ乳酸類含有組成物
JO3394B1 (ar) 2014-07-04 2019-10-20 Osteo Pharma B V تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام
EP3804698B1 (en) 2015-08-03 2024-01-31 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
GB201519811D0 (en) * 2015-11-10 2015-12-23 Univ Belfast Ocular compositions
CN106822043A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 利培酮缓释组合物及其制备方法
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
BR112019026225A2 (pt) * 2017-06-13 2020-06-30 The University Of British Columbia composições de pasta polimérica para liberação de fármacos
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
UY38386A (es) * 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
CA3197170A1 (en) * 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
WO2022251137A1 (en) * 2021-05-24 2022-12-01 The Regents Of The University Of California Thermoreversible polymers and methods of use thereof
US20240277654A1 (en) 2021-07-06 2024-08-22 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
EP4527389A4 (en) 2022-05-18 2026-05-06 Farm Rovi Lab Sa Extended-release injectable compositions intended for use in risperidone therapy in combination with CYP2D6 enzyme inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
PL370085A1 (pl) 2001-11-30 2005-05-16 Pfizer Inc. Polimeryczne kompozycje kontrolowanego uwalnianiazwiązków sprzyjających wzrostowi kości
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
ATE424848T1 (de) * 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
US20070149631A1 (en) * 2005-12-22 2007-06-28 Haider Karl W Base-catalyzed alkoxylation in the presense of polyoxyethylene-containing compounds

Also Published As

Publication number Publication date
MX2011001660A (es) 2011-03-25
ES2600797T3 (es) 2017-02-10
CA2731316A1 (en) 2010-02-18
BRPI0917975A2 (pt) 2015-11-17
KR101626632B1 (ko) 2016-06-01
RU2504360C2 (ru) 2014-01-20
US9155696B2 (en) 2015-10-13
KR20110042309A (ko) 2011-04-26
CN102119022A (zh) 2011-07-06
MX347056B (es) 2017-04-10
PT2323623T (pt) 2016-11-04
CN102119022B (zh) 2015-09-09
AU2009281223B2 (en) 2014-01-09
EP2323623B1 (en) 2016-07-27
RU2011108666A (ru) 2012-09-20
US20110183905A1 (en) 2011-07-28
EP2323623A1 (en) 2011-05-25
CA2731316C (en) 2017-10-03
AU2009281223A1 (en) 2010-02-18
WO2010018159A1 (en) 2010-02-18
JP2015129145A (ja) 2015-07-16
JP2011530568A (ja) 2011-12-22
JP5951991B2 (ja) 2016-07-13

Similar Documents

Publication Publication Date Title
GB0814695D0 (en) Pharmaceutical compositions
PT2323623T (pt) Composições farmacêuticas
IL247741A0 (en) pharmaceutical preparations
IL228817A0 (en) Pharmaceutical compounds
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
IL211886A0 (en) Solid pharmaceutical composition
IL208387A0 (en) Pharmaceutical composition
GB0707127D0 (en) Pharmaceutical compositions
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA201100871B (en) Solid pharmaceutical composition
GB0709811D0 (en) Pharmaceutical compositions
IL206487A0 (en) Pharmaceutical compositions
ZA201006224B (en) Pharmaceutical composition
GB2464200B (en) Pharmaceutical composition
GB0712454D0 (en) Pharmaceutical compositions
GB0817969D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
EP2236135A4 (en) STABLE PHARMACEUTICAL COMPOSITION
GB0806283D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0804485D0 (en) Novel pharmaceutical compositions